Clinical Report: Correction on Efficacy of Long-Acting Injectable Antipsychotics

Overview

This report corrects the p-value associated with the clinical efficacy of long-acting injectable antipsychotics for schizophrenia spectrum disorders. The corrected p-value is <0.017, indicating significant findings in real-world evidence supporting LAIs.

Background

Schizophrenia affects approximately 1% of the global population and is a leading cause of disability. Effective management of this condition is critical, as ongoing treatment with antipsychotic medications can significantly reduce the risk of relapse. Long-acting injectable antipsychotics (LAIs) represent an important treatment option that may enhance medication adherence and improve clinical outcomes.

Data Highlights

No numerical data is presented in the correction article.

Key Findings

• The corrected p-value for the efficacy of LAIs is <0.017.
• LAIs have been shown to improve adherence compared to oral antipsychotics.
• Patients on LAIs demonstrated better clinical quality outcomes post-hospitalization than those switched to oral medications.
• Guidelines recommend considering LAIs earlier in treatment to improve adherence and reduce relapse rates.
• Real-world studies indicate LAIs are associated with lower hospitalization rates compared to oral antipsychotics.

Clinical Implications

Clinicians should consider the use of long-acting injectable antipsychotics for patients with schizophrenia to enhance adherence and reduce the risk of relapse. The corrected statistical findings underscore the importance of accurate data in guiding treatment decisions.

Conclusion

The correction of the p-value highlights the significant clinical efficacy of long-acting injectable antipsychotics. This reinforces the need for ongoing evaluation and adherence to updated clinical guidelines.

Related Resources & Content

1. BMC Psychiatry, 2026 -- Correction: Real-World Evidence on the Clinical Efficacy of Long-Acting Injectable Antipsychotics for Schizophrenia Spectrum Disorders
2. BMC Psychiatry (Springer) — Efficacy of Long-Acting Injectable Antipsychotics in Treating Schizophrenia Spectrum Disorders: Evidence from Real-World Mirror-Image Studies
3. Drugs - Real World Outcomes — Clinical Quality Outcomes After Hospitalization in US Schizophrenia Patients Treated with Long-Acting Injectables Versus Those Transitioned to New Oral Antipsychotics: A Retrospective Cohort Analysis
4. BMC Psychiatry (Springer) — Single- and multiple-dose pharmacokinetics, safety, and tolerability of Aripiprazole once-monthly, long-acting intramuscular injection for Chinese adults with schizophrenia
5. Drugs - Real World Outcomes — Erratum: Monthly Long-Acting Injectable Aripiprazole for Schizophrenia Patients with Concurrent Substance Use Disorders: Findings from a Multicenter Observational Study
6. Efficacy of Long-Acting Injectable Antipsychotics in Treating Schizophrenia Spectrum Disorders
7. Clinical Quality Outcomes After Hospitalization in US Schizophrenia Patients
8. Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia
9. Latency to Long-Acting Injectable Antipsychotic Initiation and Psychiatric Hospitalization in First-Episode Schizophrenia
10. Antipsychotic Treatment Pathways, Real-World Adherence, Healthcare Resource Utilization, and Healthcare Costs Among Patients With Schizophrenia Treated With Once-Monthly, Once-Every-Three-Months, and Once-Every-Six-Months Paliperidone Palmitate in the United States - ScienceDirect